期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

调血脂药物使用情况调查分析

An Analysis of the Use of the Lipid-lowering Agents Drugs in a Large General Hospital
下载PDF
导出
摘要 目的 :了解调血脂药物使用情况和发展趋势 ,引导临床合理用药。方法 :采用限定日剂量 (DDD)为计算单位 ,对中山医科大学附属第三医院 1999～ 2 0 0 0年调血脂药物的销售金额、总用药人次 (DDDs)的排序、按药理分类的DDDs比较和药物来源的DDDs比较等进行统计分析。结果 :调血脂药物DDDs年增长率 19.0 9% ,销售金额年增长率3 6.18% ,HMG CoA还原酶抑制药的DDDs年增长率 74.0 4% ,合资企业生产的调血脂药物的DDDs两年间上升 74.0 4% ,销售金额两年间上升 5 5 .2 7%。结论 Objective:To find out the current situation and tendency of the use of the lipid lowering agents in the authors' hospital and to provide guideline for rational use of drug. Methods:The data regarding the use of lipid lowering agents in the authors' hospital during 1999 2000 were collected and analyzed in respect to the total expense, the order of DDDs, pharmacological classification and source of drug. Results:The annual rates of increase was 36.18% for the total expense for drug consumption, 19.09% for the DDDs of lipid lowering agents and 74.04% for the DDDs of 3 hydroxyl 3 methylglutary CoA reductase inhibitors, respectively. Conclusion:The average daily expense for lipid lowering agents in the authors' hospital was irrationally high.
作者 庄华玲 李瑞珍
机构地区 中山医科大学附属第三医院药剂科
出处 《医药导报》 CAS 2002年第4期242-243,共2页 Herald of Medicine
关键词 调血脂药物 用药分析 药物使用 合理用药 高脂血症 调查分析 Lipid lowering agents Analysis of drug use
分类号 R972.6 [医药卫生—药品] R589.2 [医药卫生—内分泌]
  • 相关文献

参考文献2

二级参考文献15

  • 1[1]Bischoff H,Angerbauer R,Bender J,et al.Cerivastatin:pharmacology of a novel synthetic and high active HMG-CoA reductase inhibitor[J].Atherosclerosis,1997,135(1):119.
  • 2[2]McClellan KJ,Wiseman LR,McTavish D.Cerivastatin[J].Drugs,1998,55(3):415.
  • 3[3]Yasunobu Y,Hayashi K,Shingu T,et al.Reduction of plasma cholesterol levels and induction of hepatic LDL receptor by cerivastatin sodium,a new inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A reductase,in dogs[J].Cardiovase Drugs Ther,1997,11(4):567.
  • 4[4]Farnier M.Cerivastatin in the treatment of mixed hyperlipidemia:the RIGHT study.The Cerivastatin Study Group.Cerivastatin gemfibrozil hyperlipidemia treatment[J].Am J Cardiol,1998,82(4B):47J.
  • 5[5]Bellosta S,Bernini F,Ferri N,et al.Direct vascular effects of HMG-CoA reductase inhibitors[J].Atherosclerosis,1998,137 Suppl:S101.
  • 6[6]Muck W,Riter W,Ochmann K,et al.Absolute and relative bioavailability of the HMG-CoA reductase inhibitor cerivastatin[J].Int J Clin Pharmacol Ther,1997,35(6):255.
  • 7[7]Boberg M,Angerbauer R,Fey P,et al.Metabolism of cerivastatin by human liver microsome in vitro.Characterization of primary metabolic pathways and of cytochrome P450 isozymes involved[J].Drug Metab Dispos,1997,25(3):321.
  • 8[8]Muck W,Riter W,Dietrich H,et al.Influence of the antacid maalox and the H2 antagonist cimetidine on the pharmacokinatics of cerivastatin[J].Int J Clin Pharmacol Ther,1997,35(6):261.
  • 9[9]Muck W,Ochmann K,Rohde G,et al.Influence of erythromycin pre-and co-treatment of single dose pharmacokinetics of the HMG-CoA reductase inhibitor cerivastatin[J].Eur J Clin Pharmacol,1998,53(6):469.
  • 10[10]Muck W,Riter W,Frey R,et al.Influence of cholestyramine on the pharmacokinetics of cerivastatin[J].Int J Clin Pharmacol Ther,1997,35(6):250.

共引文献5

医药导报
2002年 第4期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部